UK markets closed

Equillium, Inc. (EQ)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.3100+0.2500 (+12.14%)
At close: 04:00PM EDT
2.3400 +0.03 (+1.30%)
After hours: 06:26PM EDT

Equillium, Inc.

2223 Avenida De La Playa
Suite 105
La Jolla, CA 92037
United States
858 240 1200
https://www.equilliumbio.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees44

Key executives

NameTitlePayExercisedYear born
Mr. Daniel Mark BradburyExecutive Chairman158kN/A1961
Mr. Bruce D. Steel C.F.A.Co-Founder, President, CEO & Director796.95kN/A1966
Ms. Christine Zedelmayer M.B.A., P.M.P.Senior VP & COO561.75kN/A1970
Dr. Stephen Connelly Ph.D.Chief Scientific Officer & Director579.6kN/A1982
Mr. Jason A. KeyesChief Financial OfficerN/AN/A1971
Mr. Michael MooreVice President of Investor Relations & Corporate CommunicationsN/AN/AN/A
Dr. Matthew Ritter Ph.D.Senior Vice President of Corporate DevelopmentN/AN/AN/A
Mr. Joel M. RothmanChief Development OfficerN/AN/A1969
Dr. Maple Fung M.D.Chief Medical OfficerN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Corporate governance

Equillium, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.